New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Cheplapharm AG · ISIN: DE000CHP2222 · EQS - Company News (23 News)
Country: Germany · Primary market: Germany · EQS NID: 1723573
12 September 2023 10:00AM

CHEPLAPHARM opens swiss subsidiary and wins Agnes Wasem as Managing Director


EQS-News: Cheplapharm AG / Key word(s): Expansion
CHEPLAPHARM opens swiss subsidiary and wins Agnes Wasem as Managing Director

12.09.2023 / 10:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


fncls.ssp?fn=download2_file&code_str=3c4b9db2adcb399c1876a716b7f5533c

Agnes Wasem is the Managing Director of the newly founded CHEPLAPHARM Schweiz GmbH

CHEPLAPHARM Arzneimittel GmbH, headquartered in Greifswald/Germany, has established a Swiss national subsidiary in Binningen. Managing Director of the newly founded CHEPLAPHARM Schweiz GmbH is Agnes Wasem. Wasem has already held the position since August 1, 2023, and came from F. Hoffmann-La Roche Ltd in Basel.

 

CHEPLAPHARM Arzneimittel GmbH continues drive forward its internationalisation with the establishment of a Swiss subsidiary. With Agnes Wasem, an experienced pharmaceutical manager takes over the management of the Swiss site.

 

"I am very pleased that we were able to win Agnes Wasem for us. Agnes Wasem has an excellent network in the Swiss pharmaceutical industry and especially in the greater Basel area. The proximity to the local big pharma groups is of great strategic importance for us. With her know-how, her network, but also her charming appearance, Agnes Wasem fits perfectly into the requirement profile for the position of Managing Director in Switzerland and is thus an enrichment for CHEPLAPHARM", says Edeltraud Lafer, CEO of CHEPLAPHARM Arzneimittel GmbH.

 

With the entry of Agnes Wasem, CHEPLAPHARM Schweiz GmbH is fully operational. Building a team to steer future global acquisitions of established medicines from major pharmaceutical companies in Switzerland will be one of the most important tasks for the 40-year-old Agnes Wasem, who was born in Basel.

 

"I already know CHEPLAPHARM from many joint divestment projects at Roche, in which Roche products were transferred into the trusting hands of CHEPLAPHARM. To now be part of this company myself and to ensure that established medicines remain available to patients worldwide in the future fills me with pride and I am delighted to be able to build up the Swiss site for this purpose," says Agnes Wasem, explaining her move.

 

Agnes Wasem can draw on a wealth of expertise for her role at CHEPLAPHARM: After studying law at the University of Basel, she was admitted to the bar in 2011 and completed a Postgraduate Diploma in European Competition Law at King's College in London in 2014. Prior to joining CHEPLAPHARM, Agnes Wasem spent ten years in various management positions at F. Hoffmann-La Roche Ltd in Basel with a focus on legal responsibility for the company's M&A and divestment processes. Wasem started her career at various law firms in Basel and Zurich and specialised in handling legal aspects of M&A processes at an early stage.

 

 

About CHEPLAPHARM

CHEPLAPHARM is a family-owned company with headquarters in Greifswald. For over 20 years, the company has been very successful in taking over well-known and well-established medicines from the research-based pharmaceutical industry and transferring them to an existing global network of partners for production and distribution. In this way, CHEPLAPHARM ensures the continuous supply of these medicines to patients worldwide. In addition to its headquarters in Greifswald, CHEPLAPHARM operates further sites in France, Japan, Russia and Switzerland. The company employs around 650 people worldwide.

 

Weitere Informationen finden Sie unter www.cheplapharm.com.

 

Pressestelle:

CHEPLAPHARM ǀ Ziegelhof 24 ǀ 17489 Greifswald ǀ presse(at)cheplapharm.de

 



12.09.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Cheplapharm AG
Ziegelhof 24
17489 Greifswald
Germany
Phone: 03834 3914 O
E-mail: info@cheplapharm.com
Internet: www.cheplapharm.com
ISIN: DE000CHP2222
WKN: CHP222
Listed: Regulated Market in Frankfurt (Prime Standard)
EQS News ID: 1723573

Notierung vorgesehen
 
End of News EQS News Service

1723573  12.09.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1723573&application_name=news&site_id=boersengefluester

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.